{"id":"placebo-fostamatinib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fostamatinib works by selectively inhibiting Syk, a key enzyme involved in the activation of immune cells. This inhibition leads to a reduction in the production of pro-inflammatory cytokines and mediators, resulting in anti-inflammatory effects.","oneSentence":"Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:30.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic immune thrombocytopenia (cITP)"}]},"trialDetails":[{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT06564207","phase":"PHASE2","title":"Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults","status":"NOT_YET_RECRUITING","sponsor":"Inova Health Care Services","startDate":"2026-08-30","conditions":"Acute Respiratory Distress Syndrome, ARDS","enrollment":40},{"nctId":"NCT04132050","phase":"PHASE3","title":"A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-12-24","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":34},{"nctId":"NCT05593770","phase":"PHASE2, PHASE3","title":"International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response","status":"TERMINATED","sponsor":"NEAT ID Foundation","startDate":"2022-10-27","conditions":"COVID-19, SARS-CoV2 Infection, Coronavirus Infection","enrollment":28},{"nctId":"NCT04924660","phase":"PHASE2, PHASE3","title":"Novel Experimental COVID-19 Therapies Affecting Host Response","status":"COMPLETED","sponsor":"Sean Collins","startDate":"2021-07-15","conditions":"COVID-19, SARS-CoV-2 Infection, Coronavirus Infection","enrollment":1060},{"nctId":"NCT04629703","phase":"PHASE3","title":"Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2021-03-25","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia","enrollment":280},{"nctId":"NCT03764618","phase":"PHASE3","title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2019-04-24","conditions":"Warm Antibody Autoimmune Hemolytic Anemia","enrollment":90},{"nctId":"NCT04579393","phase":"PHASE2","title":"Fostamatinib for Hospitalized Adults With COVID-19","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-10-08","conditions":"Coronavirus Disease 2019","enrollment":59},{"nctId":"NCT02112838","phase":"PHASE2","title":"Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2014-10","conditions":"IGA Nephropathy","enrollment":76},{"nctId":"NCT02076399","phase":"PHASE3","title":"A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2014-07-14","conditions":"Immune Thrombocytopenic Purpura","enrollment":76},{"nctId":"NCT02076412","phase":"PHASE3","title":"A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2015-01","conditions":"Immune Thrombocytopenic Purpura","enrollment":74},{"nctId":"NCT00665626","phase":"PHASE2","title":"Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":219},{"nctId":"NCT00665925","phase":"PHASE2","title":"Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":457},{"nctId":"NCT02092961","phase":"PHASE2","title":"Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":198},{"nctId":"NCT01563978","phase":"PHASE2","title":"Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":266},{"nctId":"NCT01264770","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":644},{"nctId":"NCT01197534","phase":"PHASE3","title":"Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":913},{"nctId":"NCT01197755","phase":"PHASE3","title":"Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT01197521","phase":"PHASE3","title":"Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":923},{"nctId":"NCT01569074","phase":"PHASE2","title":"Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":163},{"nctId":"NCT01167868","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT00752999","phase":"PHASE2","title":"Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus","status":"WITHDRAWN","sponsor":"Rigel Pharmaceuticals","startDate":"2008-11","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT01276262","phase":"PHASE1","title":"Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction, Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction","enrollment":22},{"nctId":"NCT00326339","phase":"PHASE2","title":"Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)","status":"COMPLETED","sponsor":"Rigel Pharmaceuticals","startDate":"2006-08","conditions":"Rheumatoid Arthritis","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo, fostamatinib","genericName":"placebo, fostamatinib","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor. Used for Chronic immune thrombocytopenia (cITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}